TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02403037
Drug: Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)
Normalized name: INVESTIGATIONAL ANTI-NAUSEA AND ANTI-EMETIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
Study: NCT02151253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
Study: NCT02070991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00189384
Drug: ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02079870
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous (s.c. - under the skin) injection
Study: NCT02523898
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 8 weeks plus 100 mg clomiphene for 5 days
Study: NCT01899703
Drug: GSK2330672
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
Study: NCT01899703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
Study: NCT03970798
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
Study: NCT03970798
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
Study: NCT02981498
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin , fluorouracil, and leucovorin
Study: NCT03682120
Drug: MF59
Normalized name: vaccine adjuvant emulsion MF59C.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
Study: NCT04797793
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study: NCT04797793
Drug: Differin® Gel (Adapalene 0.1%, Galderma)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study medication will be self-applied topically on the affected areas of the face lightly, once daily at bedtime, avoiding contact with the mouth, eyes, and other mucous membranes for 84 consecutive days.
Study: NCT02678260
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
Study: NCT02659228
Drug: Anesthetics, Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
Study: NCT00870571
Drug: NorvasC® 10 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
Study: NCT00379574
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 750mg/m2 day 1, every 2 weeks
Study: NCT00379574
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin 50 mg/m2 day 1, every 2 weeks
Study: NCT00379574
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone 100 mg days 1-5, every 2 weeks
Study: NCT03855280
Drug: APVO101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for a total of 50 ED. The starting prophylaxis dose will be based on APVO101 recovery from PK Phase assessments (only pre-infusion and 15-30 minute post-infusion samples).
Study: NCT01847157
Drug: Epidermis anesthesia
Normalized name: Staphylococcus epidermidis
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide.
Study: NCT01847157
Drug: sham anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide.
Study: NCT00083447
Drug: TransMID™
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02755090
Drug: IV Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02192697
Drug: ASP8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00610948
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00610948
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04059094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation solution
Study: NCT00757731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hard capsule
Study: NCT00005774
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
Study: NCT00005774
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant according to current center practice, only after initiation of mechanical ventilation.
Study: NCT01722071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
Study: NCT03780725
Drug: [89Zr]Zr-BI 754111
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT02968927
Drug: 2HRbZE/4HRb
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00294788
Drug: PCC® (Lactobacillus fermentum VRI 003)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03888079
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% or 2% lidocaine with 1:100,000 epinephrine, augmented by intravenous sedation and analgesia
Study: NCT03888079
Drug: general anesthetic
Normalized name: General anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotracheal intubation, intravenous narcotic agents, and inhaled agents
Study: NCT01851369
Drug: TRC102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methoxyamine hydrochloride (TRC102) has been shown to potentiate the activity of temozolomide by preventing base excision repair (BER) and allowing cleavage of TRC102 bound deoxyribonucleic acid (DNA), which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with Temozolomide (TMZ) and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
Study: NCT03066076
Drug: Antithyroid Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug
Study: NCT02318277
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 administered intravenously (IV) every two weeks (q2w)
Study: NCT02318277
Drug: INCB024360
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB024360: Oral daily dosing
Study: NCT00179179
Drug: nutritional supplementation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
Study: NCT00002835
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002835
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002835
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01047397
Drug: 1278863A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg, 50mg, 100mg
Study: NCT01047397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00581997
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00581997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00167947
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped
Study: NCT02624089
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
Study: NCT02069184
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
Study: NCT01609140
Drug: MPSK3169A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose regimen A, repeating subcutaneous injections every 4 weeks
Study: NCT01609140
Drug: MPSK3169A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose regimen E, repeating subcutaneous injections every 4 weeks
Study: NCT01609140
Drug: MPSK3169A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose regimen D, repeating subcutaneous injections every 4 weeks
Study: NCT01609140
Drug: MPSK3169A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose regimen C, repeating subcutaneous injections every 4 weeks
Study: NCT01609140
Drug: MPSK3169A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose regimen B, repeating subcutaneous injections every 4 weeks
Study: NCT01609140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating subcutaneous injections of placebo every 4 weeks
Study: NCT01799278
Drug: MLN8237
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
Study: NCT02129556
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
Study: NCT01198548
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01198548
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04374552
Drug: Hydroxychloroquine sulfate &Azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug - Hydroxychloroquine sulfate \&Azithromycin
Study: NCT04374552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug - placebo
Study: NCT02269488
Drug: MEDI3250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI3250
Study: NCT00306722
Drug: AQUAVAN® (fospropofol disodium) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01101048
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
Study: NCT02037074
Drug: Drug: EVP-6308
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arms 1, 2, 3
Study: NCT02037074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 4
Study: NCT00667966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10/20 mg placebo in sequence in respective arm
Study: NCT00991562
Drug: IMGN901
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose escalation study. dosing on days 1, 8 and 15 every 28 days
Study: NCT03739554
Drug: CYC065
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT01610388
Drug: 500mg IV GSK1322322/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg IV
Study: NCT01610388
Drug: 1000mg oral GSK1322322/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg oral
Study: NCT01610388
Drug: 1000mg IV GSK1322322/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg IV
Study: NCT01610388
Drug: 1500mg oral GSK1322322/placebo dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg oral
Study: NCT01610388
Drug: 1500mg IV GSK1322322/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg IV
Study: NCT01610388
Drug: 2000mg IV GSK1322322J/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000mg IV
Study: NCT01610388
Drug: 3000mg IV GSK1322322J/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000mg IV
Study: NCT01610388
Drug: 1000mg IV GSK1322322J/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg IV
Study: NCT00003456
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00656474
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Placebo gel on Day 1, 3 and 5 post ablation.
Study: NCT00656474
Drug: GLYC-101 gel (1.0 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration on Day 1, 3 and 5 post laser ablation.
Study: NCT01941641
Drug: neoadjuvant FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01941641
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01503801
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
Study: NCT02194491
Drug: ASP3662
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03197155
Drug: Direct Acting Antivirals against hepatitis C virus infection
Normalized name: hepatitis C virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.
Study: NCT01105130
Drug: Oral L-Arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally 3 capsules ArginMax and 3 Placebo capsules
Study: NCT01105130
Drug: Oral L-Arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 6 capsules of ArginMax twice daily
Study: NCT03298061
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
Study: NCT03521336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline，Sham operation
Study: NCT01521364
Drug: Addition of different doses of clarithromycin.
Approvals — FDA: no, EMA: no, PMDA: no
Description: At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks.
Study: NCT02175758
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF administered orally once daily
Study: NCT03514537
Drug: Liberase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberase TM for use to enzymatically isolate cellular stromal vascular fraction
Study: NCT02636283
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pills
Study: NCT03418675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill that contains no medicine
Study: NCT02590510
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The quantity of methotrexate is different in the two groups.
Study: NCT00145327
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
Study: NCT00145327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL physiologic 0.9% normal saline for intravenous infusion.
Study: NCT03532490
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
Study: NCT01795937
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose
Study: NCT01037465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04097912
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-100mg
Study: NCT03315689
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Topical Solution
Study: NCT01507727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
Study: NCT03715166
Drug: Bumetanide Oral Solution
Normalized name: bumetanide Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution dosed at 0.5mg/mL Taken twice daily
Study: NCT03715166
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution Taken twice daily
Study: NCT03663725
Drug: Intensified protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
Study: NCT03663725
Drug: Stupp protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
Study: NCT03447756
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match
Study: NCT05951842
Drug: anesthetic method
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to one of the groups, TIVA group or Balanced anesthesia group. In TIVA group, anesthesia will be maintained by propofol and remifentanil infusion under target controlled infusion. In contrast, anesthesia will be maintained by sevoflurane and remifentanil infusion in the balanced anesthesia group.
Study: NCT03943992
Drug: YYD601 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients should take druges 30 minutes before breakfast.
Study: NCT03943992
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
Study: NCT00669331
Drug: Matched control
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg dose of Mannitol BD (twice a day) for 52 weeks
Study: NCT04124510
Drug: Brand Name: Flutiform K-haler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
Study: NCT01769118
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine will be given according to departmental protocol
Study: NCT03564145
Drug: S5G4T-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day topical cream